Armata Pharmaceuticals, Inc. (ARMP)Healthcare | Biotechnology | Los Angeles, United States | NYSE American
3.37 USD
+0.28
(9.061%)
⇧
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 3.37 |
Hot Take ↕ | Oct. 10, 2026, 9:11 a.m. EDT
Armata Pharmaceuticals presents a classic high-risk biotech dilemma where a 'Strong Buy' analyst recommendation clashes violently with deteriorating corporate fundamentals. The company is burning through cash at an alarming rate, with operating cash flow of -$25.4 million and free cash flow of -$27.4 million against a massive debt load of $314 million. The balance sheet is precarious, with a current ratio of just 0.11, meaning the company cannot cover its immediate liabilities without raising capital or cutting operations. While the phage therapy platform offers a compelling narrative for a potential Phase 3 catalyst, the financial reality suggests the stock is trading on hope rather than solvency. The recent price action shows some resilience, bouncing off lows, but the lack of dividends and the heavy reliance on external funding make this a dangerous hold for any investor not prepared for a potential dilution event or bankruptcy scenario. The statistical forecast models show no predictive power here, confirming that the price movement is driven entirely by binary clinical trial outcomes rather than value accumulation. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.106015 |
| AutoETS | 0.106071 |
| AutoARIMA | 0.106073 |
| AutoTheta | 0.205006 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 11.03 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.437 |
| Excess Kurtosis | -0.65 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.152 |
| Market Cap | 125,303,272 |
| Forward P/E | -1.65 |
| Beta | 1.41 |
| Previous Name | Armata Pharmaceuticals Inc. |
| Website | https://www.armatapharma.com |
As of Oct. 10, 2026, 9:11 a.m. EDT: Options activity shows extremely low liquidity and volume across all expirations. Call Open Interest is concentrated at out-of-the-money strikes ($7.50), suggesting speculative bets on a significant upside move, while Put Open Interest is negligible. Implied volatility is elevated relative to the low premium prices, indicating uncertainty rather than a clear directional consensus.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.031609178 |
| Address1 | 5,005 McConnell Avenue |
| All Time High | 1,960,000.0 |
| All Time Low | 0.83 |
| Ask | 3.38 |
| Ask Size | 300 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 111,030 |
| Average Daily Volume3 Month | 199,650 |
| Average Volume | 199,650 |
| Average Volume10Days | 111,030 |
| Beta | 1.41 |
| Bid | 3.25 |
| Bid Size | 100 |
| Board Risk | 9 |
| Book Value | -6.223 |
| City | Los Angeles |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.37 |
| Current Ratio | 0.109 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 3.4199 |
| Day Low | 3.0062 |
| Display Name | Armata Pharmaceuticals |
| Dividend Date | 1,557,446,400 |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,794,427,200 |
| Earnings Timestamp Start | 1,794,427,200 |
| Ebitda | -33,448,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -12.416 |
| Enterprise To Revenue | 74.924 |
| Enterprise Value | 415,304,256 |
| Eps Forward | -2.04 |
| Eps Trailing Twelve Months | -5.29 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 310 665 2963 |
| Fifty Day Average | 4.4358 |
| Fifty Day Average Change | -1.0658002 |
| Fifty Day Average Change Percent | -0.24027237 |
| Fifty Two Week Change Percent | -3.1609178 |
| Fifty Two Week High | 16.34 |
| Fifty Two Week High Change | -12.97 |
| Fifty Two Week High Change Percent | -0.7937577 |
| Fifty Two Week Low | 2.75 |
| Fifty Two Week Low Change | 0.6199999 |
| Fifty Two Week Low Change Percent | 0.22545451 |
| Fifty Two Week Range | 2.75 - 16.34 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 769,440,600,000 |
| Float Shares | 11,902,323 |
| Forward Eps | -2.04 |
| Forward P E | -1.6519607 |
| Free Cashflow | -27,409,624 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 61 |
| Fullday Change | 0.27999997 |
| Fullday Change Percent | 9.061488 |
| Fullday Price | 3.37 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | -2.17355 |
| Gross Profits | -12,048,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.67639 |
| Held Percent Institutions | 0.13456 |
| Implied Shares Outstanding | 37,181,979 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.ampliphibio.com/phoenix.zhtml?c=84981&p=irol-stockquote |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,557,446,400 |
| Last Split Factor | 1:14 |
| Long Business Summary | Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; and AP-PA03 for Pseudomonas aeruginosa. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc. |
| Long Name | Armata Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 125,303,272 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_84546611 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-17 |
| Net Income To Common | -192,178,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 156,164,311 |
| Number Of Analyst Opinions | 2 |
| Open | 3.08 |
| Operating Cashflow | -25,420,000 |
| Operating Margins | -4.10837 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 310 665 2928 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 3.37 |
| Post Market Time | 1,792,180,808 |
| Prev Name | Armata Pharmaceuticals Inc. |
| Previous Close | 3.09 |
| Price Hint | 4 |
| Price To Book | -0.54153943 |
| Price To Sales Trailing12 Months | 22.605679 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.106 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.28 |
| Regular Market Change Percent | 9.06149 |
| Regular Market Day High | 3.4199 |
| Regular Market Day Low | 3.0062 |
| Regular Market Day Range | 3.0062 - 3.4199 |
| Regular Market Open | 3.08 |
| Regular Market Previous Close | 3.09 |
| Regular Market Price | 3.37 |
| Regular Market Time | 1,792,180,800 |
| Regular Market Volume | 154,311 |
| Return On Assets | -0.25832 |
| Revenue Growth | 0.157 |
| Revenue Per Share | 0.152 |
| Sand P52 Week Change | 0.13723719 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 37,181,979 |
| Shares Percent Shares Out | 0.025899999 |
| Shares Short | 964,187 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 885,291 |
| Short Name | Armata Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0857 |
| Short Ratio | 2.77 |
| Source Interval | 15 |
| State | CA |
| Symbol | ARMP |
| Target High Price | 20.0 |
| Target Low Price | 15.0 |
| Target Mean Price | 17.5 |
| Target Median Price | 17.5 |
| Total Cash | 23,952,000 |
| Total Cash Per Share | 0.644 |
| Total Debt | 313,952,992 |
| Total Revenue | 5,543,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.29 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.17535 |
| Two Hundred Day Average Change | -3.8053503 |
| Two Hundred Day Average Change Percent | -0.5303365 |
| Type Disp | Equity |
| Volume | 154,311 |
| Website | https://www.armatapharma.com |
| Zip | 90,066 |